Skip to main content
Equibles
TSHA logo

TSHA · Taysha Gene Therapies, Inc. · Webcasts, Transcripts & Audio

Track TSHA — free

Use TSHA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TSHA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.79 -0.08 (-1.64%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.52B
Shares
325.83M
Volume · Oct 1 3.85M Avg daily vol (3M) 3.15M

Taysha Gene Therapies, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Taysha Gene Therapies, Inc. (TSHA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $4.71M −$17.62M '23 Q1 23-05-15 · $2.40M −$24.60M '23 Q2 23-08-14 · $4.75M −$117.09M '23 Q3 23-11-14 · $3.60M $47.74M '23 Q4 24-03-19 ▼27.5% $3.41M −$24.06M '24 Q1 24-06-26 ▼53.6% $1.11M −$20.93M '24 Q2 24-08-12 ▼62.3% $1.79M −$25.52M '24 Q3 24-11-13 ▼43.9% $2.02M −$18.79M '24 Q4 25-02-26 ▼32.5% $2.30M −$21.53M '25 Q1 25-05-15 ▲78.6% $1.99M −$26.88M '25 Q2 25-08-12 ▼100% $ −$32.73M '25 Q3 25-11-04 ▲171.3% $5.49M −$27.85M '25 Q4 26-03-19 ▼100% $ −$42.41M '26 Q1 26-05-06 LATEST ▼100% $ −$46.64M '26 Q2 26-08-11
Earnings call
FY26 · Q2
2026-08-11
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Confident tone TASHA-102 clinical development Regulatory pathway and FDA engagement Rett Syndrome Scientific Meeting (IRSF) data
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-22
Taysha Gene Therapies, Inc. (TSHA) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Confident tone Rett syndrome patient population and unmet need TASHA-102 (Tayshia 102) profile and efficacy Competitive positioning vs. ICV administration
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call
Confident tone Regulatory Progress with FDA Rett Syndrome Market Opportunity TASHA-102 Clinical Development
Revenue
$5.49M*
▲ 171.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript
Confident tone TASHA-102 REVEAL clinical data in Rett Syndrome Pivotal trial initiation and enrollment Commercial and launch team building
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript
Confident tone FDA and Regulatory Alignment TASHA-102 / REVEAL Pivotal Trial Natural History Data Set
Revenue
$1.99M
▲ 78.6% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript
Confident tone FDA regulatory alignment Rett syndrome disease and natural history data TSHA-102 clinical safety and efficacy
Revenue
$2.30M
▼ 32.5% YoY
Diluted EPS
$-0.08
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript
Confident tone Regulatory Pathway and FDA Alignment TSHA-102 Clinical Safety Profile Dose Escalation Completion and Dataset
Revenue
$2.02M*
▼ 43.9% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript
Confident tone TSHA-102 lead program for Rett Syndrome Clinical efficacy observations Clinical safety and dosing
Revenue
$1.79M
▼ 62.3% YoY
Diluted EPS
$-0.10
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript
Confident tone TSHA-102 clinical progress and dosing Rett Syndrome disease profile and unmet need Regulatory strategy and FDA interaction
Revenue
$1.11M
▼ 53.6% YoY
Diluted EPS
$-0.09
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-06-26
Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript
Confident tone TSHA-102 clinical progress and REVEAL trial updates Rett syndrome unmet need and market opportunity RMAT designation from FDA
Revenue
$3.41M
▼ 27.5% YoY
Diluted EPS
$-0.10
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
Confident tone TSHA-102 clinical efficacy and durability REVEAL trial design and enrollment progress Dose escalation strategy and safety monitoring
Revenue
$3.60M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript
Revenue
$4.75M
Diluted EPS
$-0.93
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Taysha Gene Therapies, Inc. (TSHA) Q2 2023 Earnings Call Transcript
Revenue
$2.40M
Diluted EPS
$-0.38
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Taysha Gene Therapies, Inc. (TSHA) Q1 2023 Earnings Call Transcript
Revenue
$4.71M
Diluted EPS
$-0.28
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Taysha Gene Therapies, Inc. (TSHA) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Taysha Gene Therapies, Inc. (TSHA) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.65
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Taysha Gene Therapies, Inc. (TSHA) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.85
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Taysha Gene Therapies, Inc. (TSHA) Q1 2022 Earnings Call Transcript
Diluted EPS
$-1.32
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Taysha Gene Therapies, Inc. (TSHA) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Taysha Gene Therapies, Inc. (TSHA) Q3 2021 Earnings Call Transcript
Diluted EPS
$-1.35
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Taysha Gene Therapies, Inc. (TSHA) Q2 2021 Earnings Call Transcript
Diluted EPS
$-1.09
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Taysha Gene Therapies, Inc. (TSHA) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-03
Taysha Gene Therapies, Inc. (TSHA) Q4 2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 webcasts
Key facts CIK 1806310 CUSIP 877619106 13F (30d) 5 filings 5 filers Visit website Investor relations